Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980292 | 0.95 | CASP1 (0.44) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4977104 | 0.92 | HSP90AB1 (0.41) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4979095 | 0.92 | MAPT (0.50) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4978007 | 0.91 | MAPT (0.40) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4976873 | 0.88 | MAPT (0.39) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4980252 | 0.88 | MAPT (0.48) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4979788 | 0.88 | TLR4 (0.45) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4976953 | 0.87 | LMNA (0.52) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4978715 | 0.85 | LMNA (0.58) | MAPTLMNATP53POLBHSP90AB1 | |
| SCHEMBL4976932 | 0.84 | MAPT (0.59) | MAPTLMNATP53POLBHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | MAPT 2301/4885LMNA 4534/4885TP53 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.